Welcome to our dedicated page for Ascentage Pharma Group International SEC filings (Ticker: AAPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ascentage Pharma Group International (NASDAQ: AAPG) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures as a foreign private issuer. Ascentage Pharma files annual reports on Form 20‑F and current reports on Form 6‑K under the Securities Exchange Act of 1934, reflecting its status as a NASDAQ‑listed biopharmaceutical company with operations in oncology and hematology.
Recent Form 6‑K filings have furnished press releases on a range of material topics, including pivotal Phase II and Phase III clinical data for Lisaftoclax and olverembatinib, regulatory clearances from the U.S. FDA and EMA for global registrational studies such as POLARIS‑1 and GLORA, publication of olverembatinib data in gastrointestinal stromal tumors, investor conference participation, interim financial results and business updates, and corporate governance items such as indemnification agreements and interest payments related to top‑up placements. These filings help investors understand the progress of Ascentage Pharma’s apoptotic pathway inhibitors, BCR‑ABL1 inhibitor programs, and protein degrader pipeline.
On Stock Titan, each new AAPG filing is captured from EDGAR and presented with AI‑generated highlights to explain the context and key points in clear language. Users can review Form 6‑K submissions related to clinical milestones, financing activities, and board decisions, and can connect these disclosures to the company’s broader oncology strategy. While Ascentage Pharma’s core SEC reporting currently emphasizes 6‑K updates, investors can also reference its Form 20‑F annual report for a more detailed discussion of risk factors, business overview, and financial statements.
In addition, this page offers quick access to historical filings so that readers can trace how Ascentage Pharma’s hematology and solid tumor programs, global partnerships, and capital markets activities have evolved over time. AI‑assisted summaries help reduce the time needed to interpret lengthy documents, highlighting items such as major clinical trial announcements, regulatory interactions, and key corporate actions disclosed in AAPG’s SEC submissions.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Ye Changqing filed an initial ownership report showing equity awards in the company. The filing lists stock options tied to 56,550 Ordinary Shares with an exercise price of $8.1400 per share, expiring on November 26, 2035. These options vest in four equal parts on each of November 26, 2026, 2027, 2028 and 2029.
The filing also reports 66,550 restricted stock units, each representing one Ordinary Share. These RSUs vest in four equal annual installments on the same dates, from November 26, 2026 through 2029, and have no expiration date.
Ascentage Pharma Group International director Marina Bozilenko has filed an initial ownership report showing equity-based compensation holdings. She holds stock options over 53,895 Ordinary Shares with an exercise price of $8.14 per share, expiring on November 26, 2035. These options vest in four equal installments on each of November 26, 2026, 2027, 2028 and 2029.
She also holds restricted stock units representing 63,895 Ordinary Shares. Each RSU converts into one Ordinary Share upon vesting, with the RSUs vesting in four equal installments on the same dates from 2026 through 2029 and having no expiration date. This filing records existing awards and does not show any buy or sell transactions.
ASCENTAGE PHARMA GROUP INTERNATIONAL Chairman and CEO Yang Dajun filed an initial Form 3 showing his equity interests in the company. The filing reports direct ownership of 1,097,994 Ordinary Shares, along with direct holdings of options and restricted stock units tied to additional Ordinary Shares.
The derivative positions include options over 143,463 Ordinary Shares and restricted stock units over another 143,463 Ordinary Shares, vesting in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. The options have an exercise price of $8.14 per share, shown in USD based on the grant-date conversion from HKD.
Entities associated with Yang, including the Dajun Yang Dynasty Trust, his spouse, and an entity controlled by his spouse, hold 22,054,131, 312,534 and 14,089,111 Ordinary Shares, respectively. The filing states that Yang disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.
ASCENTAGE PHARMA GROUP INTERNATIONAL director David Sidransky has reported his initial equity holdings. He holds options linked to 56,550 Ordinary Shares with an exercise price of $8.14 per share, expiring on November 26, 2035. These stock options vest in four equal annual installments on each of November 26, 2026, 2027, 2028 and 2029.
He also holds 66,550 restricted stock units, each representing a right to receive one Ordinary Share upon vesting. These RSUs vest in four equal annual installments on each of November 26, 2026, 2027, 2028 and 2029 and have no expiration date. The filing does not show any open-market buying or selling activity, only existing awards.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Simon Dazhong Lu reports existing equity awards, not new trades. He holds stock options linked to 53,895 Ordinary Shares with an exercise price of 8.1400 per share, expiring on November 26, 2035, vesting in four equal parts from November 26, 2026 through 2029. He also holds restricted stock units covering 63,895 Ordinary Shares, vesting in the same four annual installments and with no expiration date.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Marc E. Lippman reports his equity holdings in the company. He holds 21,174 Ordinary Shares directly. He also holds options over 53,895 Ordinary Shares with an exercise price of $8.14 per share, based on conversion from HKD, expiring on November 26, 2035. These stock options vest in four equal annual installments on each of November 26, 2026, 2027, 2028 and 2029. In addition, he holds 63,895 restricted stock units, each representing one Ordinary Share, which vest on the same four annual dates and have no expiration date.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Debra Yu filed an initial Form 3 showing equity awards in the company. She holds stock options linked to 53,895 Ordinary Shares with an exercise price of $8.14 per share, expiring on 11/26/2035, vesting in four equal annual increments from 11/26/2026 through 2029.
She also holds restricted stock units covering 63,895 Ordinary Shares. Each RSU represents the right to receive one Ordinary Share upon vesting. These RSUs vest in four equal annual installments on 11/26/2026, 2027, 2028 and 2029 and have no expiration date.
Ascentage Pharma Group International filed a Form 6-K detailing that four preclinical studies from its oncology pipeline have been selected for poster presentations at the AACR Annual Meeting 2026 in San Diego. The work covers three novel drug candidates: the BCR-ABL inhibitor Olverembatinib (HQP1351), the FAK/ALK/ROS1 inhibitor APG-2449, and the PRC2/EED inhibitor APG-5918 across endometrial carcinoma, mantle cell lymphoma, BRAF V600E-mutant tumors and small-cell lung cancer models.
The filing also highlights that Ascentage Pharma is a commercial-stage biopharmaceutical company with two approved products in China: Olverembatinib for multiple chronic myeloid leukemia indications and Lisaftoclax for CLL/SLL after prior systemic therapy including BTK inhibitors. Both lead assets are in multiple global registrational Phase III trials, underscoring an advanced late-stage pipeline.
Ascentage Pharma Group International has called a board meeting for March 25, 2026. At this meeting, the board plans to review and, if appropriate, approve the Group’s annual results for the year ended December 31, 2025 and consider declaring a final dividend. The notice also confirms the current composition of the board, including Chairman and Executive Director Dr. Yang Dajun and a mix of non-executive and independent non-executive directors.
Ascentage Pharma Group International will release its full year 2025 unaudited financial results and provide business updates on March 25, 2026 at 7:00 pm EDT / 7:00 am HKT. The company will host investor webcasts with Q&A in both Mandarin and English, led by management.
Ascentage Pharma is a global, commercial-stage biopharmaceutical company focused on novel cancer therapies, including its approved drugs Olverembatinib and Lisaftoclax. It is running multiple registrational Phase III trials and maintains partnerships with major pharma companies and leading research institutions.